NCT05162833已完成不适用
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- UUIs
研究概览
简要总结
To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Individual completed the clinical study "Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms" (Protocol Number CRD-10-1330-01) as a subject in the Active Treatment group
- •Individual has at least ≥4 incontinence events with associated moderate or severe urgency (UUI events), with at least one UUI event per day, as recorded in the baseline 3-day voiding diary at week 0 of the clinical study "Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms" (Protocol Number CRD-10- 1330-01)
- •Individual is ambulatory and able to use the toilet independently
- •Individual has not taken antimuscarinics, anticholinergics, beta-3 agonists, alpha blockers, 5-alpha reductase inhibitors, vasopressin analogues, tricyclic antidepressants, or phenazopyridine for at least 2 weeks prior to enrollment
- •Individual is not taking diuretics or has been on a steady dose of diuretics for at least 3 months
- •Individual is able to provide informed consent
- •Individual is capable and willing to follow all study-related procedures
排除标准
- •Individual has recurrent UTI defined as ≥4 UTIs in the past 12 months
- •Female of childbearing age (≤50 years old) who is pregnant as confirmed by urine pregnancy test, or who plans to become pregnant during the study period
- •Individual has peripheral arterial disease
- •Individual has the presence of a urinary fistula, bladder stone, or interstitial cystitis
- •Individual has a diagnosis of prostate, urethral, or bladder cancer
- •Individual has morbid obesity (BMI ≥ 40)
- •Individual has clinically significant urethral stricture disease or bladder neck contracture
- •Individual has a metallic implant that is exposed above the bone surface (e.g. a bone fracture fixation plate, but not an embedded bone screw) and is located under the skin on the bottom of the foot for either foot or under the skin on the anterior aspect of the mid-thigh for either leg.
- •Individual has an implanted electrical and/or neurostimulator device (e.g. pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, sacral stimulator, bone growth stimulator, or cochlear implant)
- •Individual has been treated with percutaneous tibial nerve stimulation or pelvic floor muscle stimulation
- •Individual has been treated with onabotulinumtoxinA in the past 9 months
- •Individual has a clinically significant peripheral neuropathy
- •Individual has a history of pelvic pain as primary diagnosis in the past 12 months (VAS score of >4 (scale of 0 to 10)) Individual has neurogenic bladder (i.e. Multiple Sclerosis, Parkinson's, Spinal Cord Injury)
- •Individual has used an investigational drug, biologic, or medical device in the past 4 weeks
- •Individual is deemed unsuitable for enrollment in the study by the investigator based on the subject's history or physical examination
研究组 & 干预措施
Maintenance group
Experimental
Subjects that completed the clinical study "Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms" that were in the active treatment group will be offered to extend treatment for 3 months.
干预措施: TheraNova Neuromodulation Device (Device)
结局指标
主要结局
UUIs
时间窗: 12 weeks
change in the mean number of urge urinary incontinence (UUI) episodes per day from week 12 to week 24 (this study starts at 12 weeks)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder SymptomsOveractive BladderNCT04758247Theranova, L.L.C.12
招募中
不适用
Sacral Neuromodulation for Male Overactive Bladder (MOAB)Urinary Urgency IncontinenceOveractive BladderBenign Prostatic HyperplasiaProstate CancerOveractive BladderBenign Prostatic HyperplasiaProstate CancerUrinary Urgency IncontinenceProstatectomyUrinary FrequencyNCT06511141Axonics, Inc.150
已完成
不适用
Deep Brain Stimulation (DBS) for the Suppression of TremorTremorAction TremorTremor, LimbEssential TremorNCT02087046Abbott Medical Devices127
已完成
不适用
Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2)Overactive BladderNCT05226286MedtronicNeuro188
招募中
不适用
Bilateral Nucleus Accumbens Focused Ultrasound Neuromodulation for Stimulant Use DisorderPsychostimulant Use Disorder(PUD)NCT06474026Korea University Anam Hospital15